Latest filing published 07 Sept 2021 for Prelude Therapeutics Inc, €184k.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Christopher Pierce: trading record in brief
This profile gathers the share dealings of Christopher Pierce in Prelude Therapeutics Inc, where the filings describe the role as chief executive. The record holds 11 filings, for trades running from 29 September 2020 to 2 September 2021.
The open-market side counts 1 purchase for €61k alongside 6 sales for €741k. The net balance comes to €680k on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 2 share grants and 2 option exercises. Since January 2021: no purchases and 6 sales on the market.
The latest filing, published on 7 September 2021, reports an open-market sale of €113k in Prelude Therapeutics Inc. The last purchase on record was published on 29 September 2020, which is 2,232 days ago. Filings reach the SEC (Form 4) feed a median of 5 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Christopher Pierce
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 17,000 shares@ US$12.85100.0% of flowCommon StockSEC:0001209191-21-055072:0
1 of 1 declaration
